ESMO Congress 2022
![Deborah Schrag](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/deborah-schrag/11859070-1-eng-GB/deborah-schrag_i770.jpg)
Can telehealth be a genuine replacement for face-to-face healthcare?
In the post-COVID-19 era, there is a need to evaluate the quality, safety and effectiveness of telehealth to deliver cancer care says ESMO Keynote Lecturer Dr Deborah Schrag
![Rugo_PP Breast_9.09](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2022/onsite/rugo_pp-breast_9.09/12213170-3-eng-GB/rugo_pp-breast_9.09_i770.jpg)
Overall survival data further support sacituzumab govitecan in HR+/HER2– metastatic breast cancer
Findings from the TROPiCS-02 trial show an overall survival benefit of sacituzumab govitecan in heavily pre-treated patients but raise questions about its optimal clinical implementation
![Audience_generic](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2022/onsite/audience_generic/12216539-1-eng-GB/audience_generic_i770.jpg)
MONARCH 3: trend for improved overall survival with abemaciclib plus aromatase inhibitor in advanced breast cancer
An interim analysis of phase III data further supports the use of abemaciclib plus non-steroidal aromatase inhibitor in patients with HR+, HER2– advanced breast cancer
![LAG3 inhibitors are changing the landscape of immunotherapy](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2022/editorial/lag3-inhibitors-are-changing-the-landscape-of-immunotherapy/12131870-1-eng-GB/lag3-inhibitors-are-changing-the-landscape-of-immunotherapy_i770.jpg)
LAG3 inhibitors are changing the landscape of immunotherapy
After impressive results were achieved in melanoma, there is now great interest in exploring the potential of dual LAG3/PD-1 inhibition in other tumour types
![Venue_external_ESMO 2022](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2022/onsite/venue_external_esmo-2022/12211916-1-eng-GB/venue_external_esmo-2022_i770.jpg)
How to integrate tebentafusp in the checkpoint-based clinical management of patients with uveal melanoma?
Since its approval, tebentafusp is changing the treatment landscape for patients with metastatic uveal melanoma, but many questions remain
![Congress_audience_01](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-stock/congress_audience_01/9864550-1-eng-GB/congress_audience_01_i770.jpg)
Immune checkpoint inhibition disappoints in relapsed platinum-sensitive ovarian cancer
Addition of the PD-L1 inhibitor atezolizumab to chemotherapy plus bevacizumab showed little or no benefit in the relapsed setting, echoing previous data from front-line therapy
![Ledermann_PP Gynae_9.09](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2022/onsite/ledermann_pp-gynae_9.09/12212057-2-eng-GB/ledermann_pp-gynae_9.09_i770.jpg)
Two studies report long-term survival benefits with olaparib in ovarian cancer
The PARP inhibitor shows durable clinical benefits in HRD+ patients with advanced disease reinforcing the importance of testing for BRCA mutations and/or HRD status.
![Opening press conference](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2022/onsite/opening-press-conference/12212936-1-eng-GB/opening-press-conference_i770.jpg)
Cancer prevention: ESMO partnering with EONS on a year-long campaign
The Society takes a further step toward improving oncologists’ knowledge on healthy lifestyles to better support their patients and reduce the burden of cancer
![Opening ceremony_ESMO 2022](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2022/onsite/opening-ceremony_esmo-2022/12213059-1-eng-GB/opening-ceremony_esmo-2022_i770.jpg)
Celebrating the new era of oncology
The annual ESMO Congress returns to be an onsite event after two years of COVID-19 pandemic, offering attendees opportunities to share knowledge on how to integrate molecular and digital tools into oncology
![W4O Forum](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/w4o-forum/11920787-1-eng-GB/w4o-forum_i770.jpg)
Gender equity in oncology – are we nearer to close the gender gap?
At the ESMO Women for Oncology Forum, international experts will discuss the latest data on female representation in the field